EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A comparative study of adaptive trial designs for dose optimization

Jingyi Zhang, Xin Chen, Bosheng Li, Fangrong Yan iD

Pharmaceutical Statistics · 2023-09 · 22 (5) · 797-814

DOI: 10.1002/pst.2306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Statistics, online erschienen am 08.05.2023. Verfasst von Jingyi Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, the US Food and Drug Administration Oncology Center of Excellence initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. The agency pointed out that the current paradigm for dose selection—based on the maximum tolerated dose (MTD)—is not sufficient for molecularly targeted therapies and immunotherapies, for which efficacy may not increase after the dose reaches a certain level. In these cases, it is more appropriate to identify the optimal biological dose (OBD) that optimizes the risk–benefit tradeoff of the drug. Project Optimus has spurred tremendous interest and urgent need for guidance on designing dose optimization trials. In this article, we review several representative dose optimization designs, including model‐based and model‐assisted designs, and compare their operating characteristics based on 10,000 randomly generated scenarios with various dose‐toxicity and dose‐efficacy curves and some fixed representative scenarios. The results show that, compared with model‐based designs, model‐assisted methods have advantages of easy‐to‐implement, robustness, and high accuracy to identify OBD. Some guidance is provided to help biostatisticians and clinicians to choose appropriate dose optimization methods in practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansDose-Response Relationship, DrugMedical OncologyResearch DesignImmunotherapyMaximum Tolerated DoseComputer SimulationBayes TheoremAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

dose optimizationmodel-assisted designsoptimal biological dosephase I-II designsrisk-benefit tradeoff

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Fangrong Yan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, J., Chen, X., Li, B., & Yan, F. (2023). A comparative study of adaptive trial designs for dose optimization. Pharmaceutical Statistics, 22(5), 797-814. https://doi.org/10.1002/pst.2306

Vancouver

Zhang J, Chen X, Li B, Yan F. A comparative study of adaptive trial designs for dose optimization. Pharmaceutical Statistics. 2023;22(5):797-814. doi:10.1002/pst.2306

BibTeX
@article{Zhang2023,
  author = {Zhang, Jingyi and Chen, Xin and Li, Bosheng and Yan, Fangrong},
  title = {A comparative study of adaptive trial designs for dose optimization},
  journal = {Pharmaceutical Statistics},
  year = {2023},
  volume = {22},
  number = {5},
  pages = {797--814},
  doi = {10.1002/pst.2306}
}
Kostenlos starten →